Approaches to Achieving Treatment Objectives for Patients with MODERATE TO SEVERE ASTHMA
Learn More & View Event »
Can Biologics Targeting Type 2 Inflammatory Mediators Play a Role in the Management of Patients with COPD?
Learn More & View Event »
Individualizing Patient Care in COPD: Treating the Underlying Endophenotype and Use of Multidisciplinary Teams
This enduring activity is designed to provide healthcare professionals with a comprehensive understanding of the role of type 2 inflammation in the pathophysiology of Chronic Obstructive Pulmonary Disease (COPD) and its implications for treatment strategies. The latest developments in the treatment of COPD using approved and investigational biologics will be discussed featuring evidence-based and real-world experiences. Participants will gain valuable insights into improving the management of COPD using a multidisciplinary approach.
RELEASED DATE: May 17, 2025
EXPIRATION DATE: May 17, 2026
Management of Chronic Obstructive Pulmonary Disease Using Evidence-Based Approaches
Learn More & View Event »
Moderate-to-Severe Asthma: Targeting Underlying Inflammatory Processes to Improve Patient Outcomes
This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
Navigating the Complexities of Moderate-to-Severe Asthma from Diagnosis to Treatment Selection in Veteran Patients
Veterans face a unique and heightened burden from moderate-to-severe asthma, experiencing worsened morbidity and mortality due to the condition. This grand rounds enduring is designed to equip healthcare professionals in the VA setting with practical, evidence-based strategies to improve care for veteran patients with moderate-to-severe asthma. Through interactive, case-based learning, participants will enhance their understanding of type 2 inflammation, gain proficiency in the use of biologic therapies, and learn to individualize treatment plans to their veteran patients’ needs, all with the goal of improving outcomes for veteran patients with moderate-to-severe asthma.
RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026
Personalized Treatment to Improve Breathing and Reduce Inflammation in Patients with Moderate-to-Severe Asthma
This enduring activity is designed to enhance healthcare professionals’ understanding of the role of type 2 inflammation in asthma’s complex pathology and its impact on disease progression. Participants will explore evidence-based approaches for incorporating biologic therapies into individualized treatment plans and learn strategies for selecting the most appropriate biologic therapy based on patient-specific needs, preferences, and goals to optimize outcomes in moderate-to-severe asthma management. The program will also review GINA recommendations and when to incorporate biologic therapy.
RELEASED DATE: October 30, 2025
EXPIRATION DATE: October 30, 2026
Reducing Exacerbations and Improving Lung Function with Targeted Therapy in Moderate-To-Severe Asthma
Learn More & View Event »
Reducing the Usage of Oral Corticosteroids in the Management of Asthma – A Part of the BREATHE Initiative
Thursday, May 30, 2024
7:00PM – 8:00PM ET
Please note this Clinical Conversation program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.
Targeting Inflammation Phenotype and Improving Lung Function in Moderate-to-Severe Asthma
This enduring activity is designed to provide healthcare professionals with the latest evidence and strategies for managing moderate-to-severe asthma, focusing on biologic therapies. The program will review all the available tools required to make informed decisions about choosing the right biologic treatment options along with providing patient-centered communication and education to improve the overall management of patients suffering with this restrictive lung condition.
RELEASED DATE: May 17, 2025
EXPIRATION DATE: May 17, 2026
